Table 1.
Characteristics of Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection, by Group
| Variables | Whole Cohort (n = 230) | Group 1 (n = 143) | Group 2 (n = 54) | Group 3 (n = 33) |
|---|---|---|---|---|
| Recipient age at transplantation, y | ||||
| Median (IQR) | 50.0 (28.8–59.5) | 48.5 (23.7–58.3) | 51.2 (31.7–61.1) | 51.8 (38.0–61.2) |
| <21 | 46 (20) | 31 (22) | 11 (20) | 4 (12) |
| 21–60 | 128 (56) | 82 (57) | 27 (50) | 19 (58) |
| >60 | 56 (24) | 30 (21) | 16 (30) | 10 (30) |
| Year of transplantation | ||||
| 2003–2010 | 135 (59) | 78 (55) | 38 (70) | 19 (58) |
| 2011–2015 | 85 (37) | 58 (41) | 15 (28) | 12 (36) |
| 2000–2002 | 10 (4) | 7 (5) | 1 (2) | 2 (6) |
| Recipient sex | ||||
| Male | 136 (59) | 86 (60) | 28 (52) | 22 (67) |
| Female | 94 (41) | 57 (40) | 26 (48) | 11 (33) |
| Race | ||||
| White | 151 (66) | 90 (63) | 37 (69) | 24 (73) |
| Other than white | 68 (30) | 46 (32) | 13 (24) | 9 (27) |
| Unknown | 11 (5) | 7 (5) | 4 (7) | … |
| Cell source | ||||
| PBSC | 163 (71) | 104 (73) | 34 (63) | 25 (76) |
| BM/CB | 67 (29) | 39 (27) | 20 (37) | 8 (24) |
| Donor type | ||||
| Allogeneic/unrelated | 171 (74) | 101 (71) | 42 (78) | 28 (85) |
| Autologous | 59 (26) | 42 (29) | 12 (22) | 5 (15) |
| No. of transplantations | ||||
| 1 | 187 (81) | 121 (85) | 40 (74) | 26 (79) |
| 2 | 40 (17) | 21 (15) | 14 (26) | 5 (15) |
| 3 | 3 (1) | 1 (1) | 0 (0) | 2 (6) |
| Morphologic relapse | ||||
| No | 219 (95) | 135 (94) | 52 (96) | 32 (97) |
| Yes | 11 (5) | 8 (6) | 2 (4) | 1 (3) |
| Acute GVHD | ||||
| Grade 0–2 | 133 (58) | 77 (54) | 34 (63) | 22 (67) |
| Grade 3–4 | 32 (28) | 18 (13) | 8 (15) | 6 (18) |
| FEV1 percentage prior to transplantation | ||||
| <80 | 49 (21) | 31 (22) | 12 (22) | 6 (18) |
| ≥80 | 148 (64) | 93 (65) | 32 (59) | 23 (70) |
| Missing | 33 (14) | 19 (13) | 10 (19) | 4 (12) |
| FEV1/FVC prior to transplantation | ||||
| <70 | 37 (16) | 23 (16) | 10 (19) | 4 (12) |
| ≥70 | 162 (70) | 104 (73) | 33 (61) | 25 (76) |
| Missing | 31 (13) | 16 (11) | 11 (20) | 4 (12) |
| DLCO percentage prior to transplantation | ||||
| <80 | 109 (47) | 66 (46) | 25 (46) | 18 (55) |
| ≥80 | 82 (36) | 53 (37) | 18 (33) | 11 (33) |
| Missing | 39 (17) | 24 (17) | 11 (20) | 4 (12) |
| Days to first diagnosis of RSV infection after transplantation, median (IQR) | 128.5 (50–422) | 90.0 (50–407) | 121.5 (48–405) | 152.0 (114–499) |
| Bronchiolitis obliterans prior to RSV infection | ||||
| No | 226 (98) | 143 (100) | 52 (96) | 31 (94) |
| Yes | 4 (2) | 0 (0) | 2 (4) | 2 (6) |
| RSV testing method | ||||
| PCR | 168 (73) | 97 (68) | 44 (81) | 27 (82) |
| Non-PCR | 62 (27) | 46 (32) | 10 (19) | 6 (18) |
| Oxygen use at first diagnosis of RSV infection | ||||
| None | 201 (87) | 140 (98) | 45 (83) | 16 (48) |
| ≤2 L/min | 4 (2) | … | 3 (6) | 1 (3) |
| >2 L/min | 19 (8) | 3 (2) | 6 (11) | 10 (30) |
| MV | 6 (3) | … | … | 6 (18) |
| Steroid use at first diagnosis of RSV infection | ||||
| None | 144 (63) | 95 (66) | 30 (56) | 19 (58) |
| ≤1 mg/kg/day | 68 (30) | 41 (29) | 16 (30) | 11 (33) |
| >1 mg/kg/day | 18 (8) | 7 (5) | 8 (15) | 3 (9) |
Data are no. (%) of subjects, unless otherwise indicated.
Abbreviations: BM, bone marrow; CB, cord blood; DLCO diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume, 1 second; FVC, forced vital capacity; GVHD, graft-versus-host disease; IQR, interquartile range; PBSC, peripheral blood stem cell; PCR, polymerase chain reaction.